Share on StockTwits

Equities research analysts at Leerink Swann started coverage on shares of Immune Design Corp (NASDAQ:IMDZ) in a research note issued to investors on Tuesday. The firm set an “outperform” rating on the stock.

Several other analysts have also recently commented on the stock. Analysts at Wells Fargo & Co. initiated coverage on shares of Immune Design Corp in a research note on Monday. They set an “outperform” rating on the stock. Analysts at Jefferies Group initiated coverage on shares of Immune Design Corp in a research note on Monday. They set a “buy” rating and a $15.00 price target on the stock.

Shares of Immune Design Corp (NASDAQ:IMDZ) traded up 2.80% during mid-day trading on Tuesday, hitting $12.47. The stock had a trading volume of 21,973 shares. Immune Design Corp has a 1-year low of $11.51 and a 1-year high of $12.81. The stock’s 50-day moving average is $12.12 and its 200-day moving average is $12.12. The company’s market cap is $196.6 million.

Immune Design Corp is a clinical-stage immunotherapy company. The Company has engineered its technologies to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells (NASDAQ:IMDZ), to fight cancer.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.